Skip to contentP
Phathom Pharmaceuticals, Inc.
P
PHATPhathom Pharmaceuticals, Inc. Q3 2025 · 10-Q
Revenue$49.50M$49.50M+202.7% vs Q3 2024 Net Income-$29.97M-$29.97MN/M vs Q3 2024 EPS Diluted-$0.41-$0.41N/M vs Q3 2024 Gross Profit$43,314,000+209.5% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Phathom Pharmaceuticals, Inc. · CIK 1783183 · Engraved from SEC EDGAR
Operating Cash Flowderived-$14,115,000N/M Free Cash Flowderived-$14,142,000N/M Margins · derivedGross margin87.5%+1.9 pt vs Q3 2024
Operating margin-30.8%+402.1 pt vs Q3 2024
Net margin-60.5%+462.8 pt vs Q3 2024
ended Sep 30, 2025 · filed Oct 30, 2025 · 30 d after period end